Can you take Penpulimab with Quadramet?

Penpulimab has a moderate potential interaction with Autoimmune Disorders.

Programmed death receptor-1/ligand-1 (PD-1/PD-L1) blocking antibodies can cause immune-mediated adverse reactions, which may be severe or fatal. Immune-mediated adverse reactions can occur in any organ system or tissue at any time after starting therapy. This may be considered when using PD-1/PD-L1 blocking antibodies in patients with immune system disorders (e.g., ulcerative colitis, Crohn's disease, lupus) or with conditions affecting the nervous system (e.g., myasthenia gravis, Guillain-Barre syndrome). It is recommended to monitor patients closely for signs/symptoms that may be clinical manifestations of underlying immune-mediated adverse reactions.

Penpulimab has a moderate potential interaction with Bone Marrow Transplantation.

Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a programmed death receptor-1/ligand-1 (PD-1/PD-L1) blocking antibody. Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between PD-1/PD-L1 blockade and allogeneic HSCT. It is recommended to follow patients closely for evidence of transplant-related complications and intervene promptly. The benefit versus risks of treatment with a PD-1/PD-L1 blocking antibody before or after an allogeneic HSCT should be considered.

Penpulimab has a moderate potential interaction with History, Radiation Therapy.

Penpulimab can cause immune-mediated pneumonitis. In general, the incidence of pneumonitis was higher in patients with prior thoracic radiation.

Penpulimab has a moderate potential interaction with Liver Disease.

The effect of severe hepatic dysfunction (total bilirubin greater than 3 times ULN and any AST) on the pharmacokinetics of penpulimab is unknown. Additionally, this drug can cause immune-mediated hepatitis and hepatotoxicity. Evaluate liver enzymes at baseline and periodically during treatment.

Penpulimab has a moderate potential interaction with Organ Transplant.

Solid organ transplant rejection and other transplant (including corneal graft) rejection have been reported with the use of programmed death receptor-1/ligand-1 (PD-1/PD-L1) blocking antibodies. This may be considered when using PD-1/PD-L1 blocking antibodies in patients who have received a solid organ or other transplant.

Penpulimab has a moderate potential interaction with Renal Dysfunction.

The effect of severe renal dysfunction (CrCl below 30 mL/min) on the pharmacokinetics of penpulimab is unknown. Additionally, this drug can cause immune-mediated nephritis and renal dysfunction. Patients should be monitored for early identification and management. Evaluate creatinine levels at baseline and periodically during treatment.